Softwr

Healthcare · head to head

Oracle Clinical One vs Paige

Oracle Clinical One logo

Oracle Clinical One

Healthcare

Unified clinical trial data collection and randomisation on one Oracle Life Sciences platform

From
On request
Rated
-
Full reviewWebsite
Paige logo

Paige

Healthcare

Digital pathology AI holding the first FDA De Novo authorisation for a pathology algorithm, now part of Tempus

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Oracle Clinical One nothing about the commercial terms is published, so cost, implementation length and validation scope all emerge inside an enterprise sales process, and comparison shopping requires running parallel procurements.; Paige the FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • They diverge on capability: Oracle Clinical One covers Unified platform, Paige covers Paige Prostate Detect.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Oracle Clinical One and Paige actually diverge.

Attributes where Oracle Clinical One and Paige differ
AttributeOracle Clinical OnePaige
PlatformsWeb, iOS, AndroidWeb, Cloud, On-premise

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Oracle Clinical One

  • Unified platform
  • Data collection
  • Randomisation and supplies
  • No-code study build
  • Regulatory compliance
  • Mid-study changes
  • Integrations
  • Cloud delivery

Only in Paige

  • Paige Prostate Detect
  • Paige Prostate Grade and Quantify
  • Perineural invasion detection
  • Breast and lymph node applications
  • FullFocus viewer
  • Foundation models
  • OmniScreen
  • Paige Alba

What people use each for

The jobs each tool is most often brought in to do.

Oracle Clinical One

  • A sponsor running a complex Phase III where randomisation errors between separate EDC and RTSM vendors have already cost timenot Paige
  • A pharmaceutical company already on Oracle Clinical or InForm that needs a supported migration path off end-of-life systemsnot Paige
  • A trial with adaptive randomisation and drug supply forecasting that would otherwise need custom programming per amendmentnot Paige
  • A CRO standardising study build across many sponsor programmes on one validated platformnot Paige

Paige

  • A reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffablenot Oracle Clinical One
  • A pathology department already digitised that wants a documented safety net against missed small foci of cancernot Oracle Clinical One
  • A hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reportingnot Oracle Clinical One
  • A pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variabilitynot Oracle Clinical One

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Oracle Clinical One

  • Nothing about the commercial terms is published, so cost, implementation length and validation scope all emerge inside an enterprise sales process, and comparison shopping requires running parallel procurements.
  • Placing data collection and randomisation with a single vendor concentrates risk: an outage or a defect affects both of the systems your sites cannot work without.
  • Mid-study amendments are routine in trials but flow through the vendor change control process, and change orders are where the real cost of an Oracle trial platform accumulates after signature.
  • Implementation and study build require specialist staff or Oracle services, so the practical time from contract to first patient in is measured in months, not weeks.
  • It is aimed squarely at sponsors and CROs with established trial operations, and a small biotech running its first study will find the platform, the contracting and the validation burden heavier than its team can absorb.

Paige

  • The FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • The algorithm is worthless without a digital pathology programme already running, and slide scanning, storage and workflow typically cost far more than the software licence.
  • Tempus acquired Paige in 2025, so the roadmap now competes for attention inside a genomics-led business, and the pathology-only buyer is no longer the primary customer.
  • Scanner compatibility is a hard constraint rather than a preference, and a laboratory with an unsupported scanner fleet cannot use the authorised indication at all.
  • Pricing is per case or per slide and unpublished, so a laboratory cannot model cost per reported case without entering a sales process.

Pricing, plan by plan

Oracle Clinical One

On request
  • Clinical One Data Collection$undefined/year
    • Pricing only through Oracle sales
    • Priced against study count, sites and subjects
    • Study build and configuration services quoted separately
  • Clinical One Randomization and Supplies Management$undefined/year
    • Quoted alongside or independently of Data Collection
    • Randomisation strategy configuration included in the service
    • Supply forecasting and kit management

Paige

On request
  • Paige clinical applications$undefined/year
    • Priced per case or per slide analysed under annual agreement
    • Prostate, breast and other applications licensed separately
    • Requires compatible whole slide scanner and the FullFocus viewer for the authorised indication

Which should you pick?

Choose Oracle Clinical One if

  • You need unified platform.
  • You work on Web, iOS, Android.
  • You also want data collection.
Oracle Clinical One review

Choose Paige if

  • You need paige prostate detect.
  • You work on Web, Cloud, On-premise.
  • You also want paige prostate grade and quantify.
Paige review

Questions people ask

Is Oracle Clinical One or Paige better?
Neither clearly leads. Oracle Clinical One starts at On request and Paige at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Oracle Clinical One or Paige?
Oracle Clinical One starts at On request and Paige at On request.
Does Oracle Clinical One or Paige run on more platforms?
Oracle Clinical One runs on Web, iOS, Android. Paige runs on Web, Cloud, On-premise.
What is Oracle Clinical One best used for?
Oracle Clinical One is most often used for a sponsor running a complex phase iii where randomisation errors between separate edc and rtsm vendors have already cost time, a pharmaceutical company already on oracle clinical or inform that needs a supported migration path off end-of-life systems, a trial with adaptive randomisation and drug supply forecasting that would otherwise need custom programming per amendment, a cro standardising study build across many sponsor programmes on one validated platform. Of those, a sponsor running a complex phase iii where randomisation errors between separate edc and rtsm vendors have already cost time and a pharmaceutical company already on oracle clinical or inform that needs a supported migration path off end-of-life systems are not what Paige is typically brought in for.
What can Oracle Clinical One do that Paige cannot?
Oracle Clinical One covers Unified platform, Data collection, Randomisation and supplies, No-code study build. Paige covers Paige Prostate Detect, Paige Prostate Grade and Quantify, Perineural invasion detection, Breast and lymph node applications.

Answered from the vendors’ own pages

Oracle Clinical One: What replaced Oracle Clinical and InForm?

Clinical One is the current Oracle Life Sciences platform, and sponsors on the older Oracle Clinical and InForm products are the primary migration audience.

Paige: What exactly is FDA authorised?

Paige Prostate Detect, as an adjunct for identifying areas of interest on digitised prostate core needle biopsy slides, viewed through the Paige FullFocus viewer on a compatible scanner. Nothing else in the portfolio holds that authorisation in the United States.

Oracle Clinical One: Can I buy randomisation without data collection?

Yes. Clinical One Randomization and Supplies Management can integrate with a third-party EDC if you want to keep an incumbent capture system.

Paige: Is the European position broader?

Yes. The Paige Prostate suite including grading and quantification received IVDR certification in 2025, which covers more than the United States authorisation.

Oracle Clinical One: Is pricing published?

No. Every element, including licence, study build, implementation and validation, comes through Oracle sales.

Paige: What did the pivotal study measure?

Pathologist cancer detection on individual slide images improved, with reported reductions in false negative and false positive readings. It measured pathologist performance with the tool, not standalone algorithm accuracy.

Oracle Clinical One: Is it validated for regulated trials?

It is delivered as a validated cloud service with GxP documentation and Part 11 aligned audit trails, but sponsor-level validation of your own configuration remains your responsibility.

Paige: Who owns Paige now?

Tempus AI acquired Paige in 2025. Products remain branded Paige.

Share

Related pages

More on Oracle Clinical One

More on Paige

Keep looking

Other head to heads